Drug Development

Encouraging phase II results reported for Galida

Published in Diabetes Week, July 11th, 2005

Phase II data presented at the 65th annual American Diabetes Association (ADA) Scientific Sessions show that Galida (tesaglitazar) is well tolerated (adverse events were dose dependent) and significantly, and dose-dependently, improves glucose control and lipid abnormalities in patients with type 2 diabetes (GLAD study).

New data from a second study (SIR) show that Galida significantly and dose-dependently improves postprandial glucose and lipid metabolism in non-diabetic subjects with manifestations of insulin resistance. phase III studies for Galida are ongoing.

Historically, the treatment of type 2 diabetes has been glucocentric with little or no...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Diabetes Week

Source: Diabetes Week (2005-07-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry